Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ733MR)

This product GTTS-WQ733MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ733MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1473MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ5034MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ13721MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ14917MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ15663MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ9419MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ14640MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ2273MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW